Kathleen Elias
Company: Seal Rock Therapeutics
Job title: Co-Founder & Vice President - Research & Translational Medicine
Seminars:
Panel Discussion: Navigating the Evolving NASH Landscape to Apprehend the Future of Combination Therapies & Optimize Treatment 2:30 pm
Deliberating the best approaches to position GLP-1s for different indications, mono therapy, and combination therapy How are we maximizing the use of injectables and oral medicines? Uniting towards a shared goal to advances towards efficacious NASH treatments through collaborative effortsRead more
day: Day 1 Seminar B Post-Lunch Tracks
SRT-015: A Second-Generation ASK1 Inhibitor for Liver Diseases Including NASH 2:00 pm
SRT-015 treatment results in direct inhibition of apoptosis, inflammation and fibrosis in vitro and in vivo Liver-selective small molecule efficacious in a chronic, therapeutic DIO-NASH preclinical model and in multiple acute liver models Demonstrated safety in Phase 1 clinical trials; ideal single or combination therapyRead more
day: Day 1 Seminar B Post-Lunch Tracks